Evaluation and improvement of the properties of the novel cystine-knot microprotein McoEeTI for oral administration

International Journal of Pharmaceutics

Volumn 332, Issue 1-2, 2007, Pages 72-79

  Werle, M ^a   Kafedjiiski, K ^b   Kolmar, H ^c,d   Bernkop Schnurch A ^b  

^a Thiomatrix Forschungs und Beratungs GmbH   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c Selecore GmbH   (Germany)

^d DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Cystine knot microprotein; Oral peptide delivery; Pharmacophoric scaffold; Thiomers

Indexed keywords

BOWMAN BIRK INHIBITOR; CHITOSAN DERIVATIVE; CHITOSAN THIOBUTYLAMIDINE; CHYMOTRYPSIN; CYSTEINE; CYSTINE KNOT MICROPROTEIN; DECANOATE SODIUM; ELASTASE; HEXANOIC ACID DERIVATIVE; PEPSIN A; PEPTIDE; POLYCARBOPHIL; PROTEIN DERIVATIVE; PROTEIN MCOEETI; PROTEINASE; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYMATIC DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOELECTRIC POINT; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; RAT; STOMACH JUICE; SWINE;

ACRYLIC RESINS; ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANIMALS; CELL MEMBRANE PERMEABILITY; CHITIN; CHYMOTRYPSIN; CYCLOTIDES; CYSTEINE; CYSTINE; CYSTINE KNOT MOTIFS; DIFFUSION CHAMBERS, CULTURE; DRUG CARRIERS; DRUG STABILITY; INTESTINAL ABSORPTION; MOLECULAR SEQUENCE DATA; PLANT PROTEINS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RATS; RECOMBINANT FUSION PROTEINS; SERINE; SWINE; TIME FACTORS; TRYPSIN; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

EID: 33846876110     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.09.028     Document Type: Article

References (21)

1. Bernkop-Schnürch A., and Fragner R. Investigations into the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administration. Pharm. Sci. 2 (1996) 361-363
2. Bernkop-Schnürch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control Rel. 52 (1998) 1-16
3. Bernkop-Schnürch A., and Thaler S. Polycarbophil-cysteine conjugates as platforms for oral (poly)peptide delivery systems. J. Pharm. Sci. 89 (2000) 901-909
4. Bernkop-Schnürch A., and Walker G. Multifunctional matrices for oral peptide delivery. Crit. Rev. Ther. Drug Carrier Syst. 18 (2001) 459-501
5. Bernkop-Schnürch A., Hornof M., and Zoidl T. Thiolated polymers-thiomers: modification of chitosan with 2-iminothiolane. Int. J. Pharm. 260 (2003) 229-237
6. Bernkop-Schnürch A., Kast C.E., and Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J. Control Rel. 93 (2003) 95-103
7. Bernkop-Schnürch A., Guggi D., and Pinter Y. Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J. Control Rel. 94 (2004) 177-186
8. Bernkop-Schnürch A., Pinter Y., Guggi D., Kahlbacher H., Schoffmann G., Schuh M., Schmerold I., Del Curto M.D., D'Antonio M., Esposito P., and Huck C. The use of thiolated polymers as carrier matrix in oral peptide delivery-proof of concept. J. Control Rel. 106 (2005) 26-33
9. Clausen A.E., and Bernkop-Schnürch A. In vitro evaluation of the permeation-enhancing effect of thiolated polycarbophil. J. Pharm. Sci. 89 (2000) 1253-1261
10. Colgrave M.L., and Craik D.J. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43 (2004) 5965-5975
11. Craik D.J., Daly N.L., and Waine C. The cystine knot motif in toxins and implications for drug design. Toxicon 39 (2001) 43-60
12. Marschütz M.K., Zauner W., Mattner F., Otava A., Buschle M., and Bernkop-Schnürch A. Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration. Peptides 23 (2002) 1727-1733
13. Niemann H.H., Schmoldt H.U., Wentzel A., Kolmar H., and Heinz D.W. Barnase fusion as a tool to determine the crystal structure of the small disulfide-rich protein McoEeTI. J. Mol. Biol. 356 1 (2006) 1-8
14. Reseland J.E., Holm H., Jacobsen M.B., Jenssen T.G., and Hanssen L.E. Proteinase inhibitors induce selective stimulation of human trypsin and chymotrypsin secretion. J. Nutr. 126 (1996) 634-642
15. Schmoldt H.U., Wentzel A., Becker S., and Kolmar H. A fusion protein system for the recombinant production of short disulfide bond rich cystine knot peptides using barnase as a purification handle. Protein Exp. Purif. 39 (2005) 82-89
16. Swarbrick J., and Boylan J.C. Encyclopedia of Pharmaceutical Technology. second ed. (2002), Marcel Dekker, Inc., New York
17. Tomita M., Shiga M., Hayashi M., and Awazu S. Enhancement of colonic drug absorption by the paracellular permeation route. Pharm. Res. 5 (1988) 341-346
18. Tomita M., Hayashi M., and Awazu S. Absorption-enhancing mechanism of sodiumcaprate and decanoylcarnitine in Caco-2 cells. J. Pharmacol. Exp. Ther. 272 (1995) 739-743
19. Ushirogawa Y. Effect of organic acids, trypsin inhibitors and dietary protein on the pharmalogical activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int. J. Pharm. 81 (1992) 133
20. Werle M., Schmitz T., Huang H., Wentzel A., Kolmar H., and Bernkop-Schnürch A. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J. Drug Target. 14 3 (2006) 137-146
21. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11 (1994) 61-95